We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 138% below its sector, cheaper than its peers on earnings.
MedPacto, Inc. is a South Korean biopharmaceutical company specializing in the research and development of novel therapeutic solutions for oncology and autoimmune conditions. The firm's pipeline includes several key drug candidates: ME-1601mAb, an investigational treatment designed to target BSP1 for various cancers; MS-1601A, which addresses both cancerous and autoimmune diseases by targeting TRG1; and vactosertib, a therapeutic candidate aimed at solid tumors. MedPacto is headquartered in Seoul, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 235980.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
